Evaluation of bone marrow in breast cancer patients: Prediction of clinical outcome and response to therapy

Breast

Volumn 12, Issue 6, 2003, Pages 397-404

  Braun, Stephan ^a   Vogl, Florian D ^b   Janni, Wolfgang ^c   Marth, Christian ^a   Schlimok, Günter ^d   Pantel, Klaus ^e  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b INSTITUTE FOR RENEWABLE ENERGY   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d KLINIKUM AUGSBURG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone marrow; Breast cancer; Micrometastasis

Indexed keywords

CARBOPLATIN; EDRECOLOMAB; EPIRUBICIN; IFOSFAMIDE; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE;

ARTICLE; BONE MARROW EXAMINATION; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TUMOR CELL; VALIDATION PROCESS;

EID: 0347519224     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00143-7     Document Type: Article

References (76)

1. Gebauer G, Fehm T, Merkle E, Beck E P, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-3674.
2. Gerber B, Krause A, Muller H et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 960-971.
3. Braun S, Pantel K, Müller P et al. Cytokeratin-positive cells in the bone marrow and Survival of patients with stage I, II or III breast cancer. N Engl J Med 2000; 342: 525-533.
4. Mansi J L, Gogas H, Bliss J M. Gazet J C, Berger U, Coombes R C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up. Lancet 1999; 354: 197-202.
5. Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 1998; 49: 27-33.
6. Diel I J, Kaufmann M, Costa S D et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996: 88: 1652-1664.
7. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
8. Cote R J, Rosen P P, Lesser M L, Old L J, Osborne M P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991: 9: 1749-1756.
9. Klein C A, Schmidt-Kittler O, Schardt J A, Pantel K, Speicher M R, Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 1999; 96: 4494-4499.
10. Klein C A, Seidl S, Petat-Dutter K et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002; 20: 387-392.
11. Klein C A, Blankenstein T J F, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689.
12. Funke I, Schraut W. Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated. J Clin Oncol 1998; 16: 557-566.
13. Goldhirsch A, Glick J H. Gelber R D, Coates A S, Senn H J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
14. Slamon D J, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
15. Braun S, Kentenich C R M, Janni W et al. Lack of effect of adjuvant chemotherapy no the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80-86.
16. Braun S, Hepp F, Kentenich C R M et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999; 5: 3999-4004.
17. Singletary S E, Allred C, Ashley P et al. Revision of the American Joint committee on cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
18. Pantel K, Enzmann T, Köllermann J, Caprano J, Riethrmüller G, Köllermann M W. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997; 71: 521-525.
19. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995; 31A: 1799-1803.
20. Ridell B, Landys K. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac creast. Cancer 1979; 44: 1782-1788.
21. Braun S, Cevatli B S, Assemi C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of nodenegative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001; 19: 1468-1475.
22. Courtemanche D J, Worth A J, Coupland R W, Rowell J L, MacFarlane J K. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. Can J Surg 1991; 34: 21-26.
23. Funke I, Fries S, Rolle M et al. Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 1996; 65: 755-761.
24. Molino A, pelosi G, Turazza M et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features. Breast Cancer Res Treat 1997; 42: 23-30.
25. Salvadori B, Squicciarini P, Rovini D et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 1990; 26: 865-867.
26. Singletary S E, Larry L, Trucker S L, Spitzer G. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991; 47: 32-36.
27. Mathieu M C, Friedman S, Bosq J et al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat 1990; 15: 21-26.
28. Porro G, Menard S, Tagliabue E et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988; 61: 2407-2411.
29. Braun S, Müller M, Hepp F, Schlimok G, Riethmüller G, Pantel K. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 1998; 90: 1099-1100.
30. Pantel K, Schlimok G, Angstwurm M et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-173.
31. Schlimok G, Funke I, Holzmann B et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672-8676.
32. Putz E, Witter K, Offner S et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999; 59: 241-248.
33. Pantel K, Dickmanns A, Zippelius A et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87: 1162-1168.
34. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
35. Pantel K, Izbicki J R. Angstwurm M et al. Immunocytochemical detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993; 53: 1027-1031.
36. Müller P, Carroll P, Bowers E et al. Low frequency epithelial cells in bone marrow from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998; 83: 538-546.
37. Borgen E, Naume B, Nesland J M et al. Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999; 1: 377-388.
38. Borgen E, Naume B, Nesland J M et al. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 2001; 46: 215-221.
39. Bauer K D, de la Torre-Bueno J, Diel I J et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000; 6: 3552-3559.
40. Kraeft S-K, Sutherland R, Gravelin L et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 2000; 6: 434-442.
41. Witzig T E. Bossy B. Kimlinger T et al. Detection of circulating cytokeratin-positive cells in blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2001; 8: 1085-1091.
42. Zippelius A, Kufer P, Honold G et al. Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15: 2701-2708.
43. Zippelius A, Lutterbuse R, Riethmuller G, Pantel K. Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. Clin Cancer Res 2001; 6: 2741-2750.
44. Berger U, Bettelheim R, Mansi J L, Easton D, Coombes R C, Neville A M. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988; 90: 1-6.
45. Cote R J, Rosen P P, Hakes T B et al. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am J Surg Pathol 1988; 12: 333-340.
46. Mansi J L, Easton D, Berger U et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Fur J Cancer 1991; 27: 1552-1555.
47. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
48. Schabel F M. Rationale for adjuvant chemotherapy. Cancer 1977; 39 (Suppl 4): 3-11.
49. Hempel D, Müller P, Oruzio D, Ehnle S, Schlimok G. Adoptive immunotherapy with monoclonal antibody 17-1A to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy. Blood 1997; 90(Suppl 1): 379B (abstract #44454).
50. Hohaus S, Funk L, Brehm M et al. Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation. Blood 1996; 88 (Suppl 10): 128A (abstract #501).
51. Cobleigh M A, Vogel C L, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
52. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
53. Goodman G E, Hellstrom I, Brodzinsky L et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 7: 1083-1092.
54. Scott A M, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997; 9: 717-722.
55. Dilliman R O. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497-1515.
56. Riethmüller G, Johnson J P. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol 1992; 4: 647-655.
57. Jain R K. Delivery of molecular medicine to solid tumors. Science 1996; 271: 1079-1080.
58. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343: 1177-1183.
59. Göttlinger H G, Funke I, Johnson J P, Gokel J M, Riethmüller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.
60. Riethmüller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-1794.
61. Scholz D, Lubeck M, Loibner H. Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies. Cancer Immunol Immunother 1991; 33: 153-157.
62. Braun S, Hepp F, Sommer H L, Pantel K. Tumor antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer (Pred Oncol) 1999; 84: 1-5.
63. Steel M. Cancer genes: complexes and complexities. Lancet 1993; 342: 754-755.
64. Kerbel R S. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990; 55: 87-131.
65. Allgayer H, Heiss M M. Riesenberg R et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997; 57: 1394-1399.
66. Pantel K, Schmaus W, Schlimok G, Riethmüller G. p53 immunostaining of megakaryocytes is preferentially observed in patients with epithelial malignancies. Blood 1993; 82: 610a (abstract).
67. Riesenberg R, Oberneder R, Kriegmair M et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells. Histochemistry 1993; 99: 61-66.
68. Pantel K, Schlimok G, Kutter D et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51: 4712-4715.
69. Schlimok G, Riethmüller G. Detection, characterization and tumorigenicity of tumor cells in human bone marrow. Semin Cancer Biol 1990; 1: 207-215.
70. Diel I J, Solomayerr E F, Costa S D et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363.
71. Untch M, Kahlert S, Funke I et al. Detection of cytokeratin 18-positive cells in bone marrow of breast cancer patients: no prediction of bad outcome. Proc ASCO 1999; 18: 639a (abstract #2472).
72. Datta Y H, Adams P T, Drobyski W R. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-482.
73. Fields K K, Elfenbein G J, Trudeau W L, Perlinss J B, Jansen W E, Moscinski L C. Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
74. Vannucchi A M, Bosi A, Glinz S et al. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haematol 1998; 103: 610-617.
75. Slade MJ, Smith B M, Sinnett H D, Cross N C P, Coombes R C. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999; 17: 870-879.
76. Lugo T G, Braun S, Cote R J, Pantel K, Rusch V. Detection and measurement of occult disease for the prognosis of solid tumours. J Clin Oncol 2003; 21(13): 2609-2615.